Unique ID issued by UMIN | UMIN000045445 |
---|---|
Receipt number | R000051881 |
Scientific Title | Screening for disease progression by measuring lower limb circumference in diabetic patients. |
Date of disclosure of the study information | 2021/09/10 |
Last modified on | 2021/09/10 14:11:19 |
Screening for disease progression by measuring lower limb circumference in diabetic patients.
Screening for disease progression by measuring lower limb circumference in diabetic patients.
Screening for disease progression by measuring lower limb circumference in diabetic patients.
Screening for disease progression by measuring lower limb circumference in diabetic patients.
Japan |
diabetes mellitus
Arteriosclerosis
Cardiology | Endocrinology and Metabolism | Rehabilitation medicine |
Others
NO
The purpose of this study was to clarify the usefulness of the evaluation of the maximum circumference of the thigh and lower leg in screening for disease progression in patients with diabetes mellitus (DM).
Efficacy
Primary endpoint: Association between femoral leg circumference ratio and DM pathological parameters in DM patients.
Factor analysis was performed using regression analysis with the femoral-femoral circumference ratio as the dependent variable.
Thigh-to-lower leg circumference ratio is the ratio of lower leg circumference to thigh circumference.
Secondary endpoints: Change from baseline in lower extremity circumference at 12 to 15 months.
Basic information: sex, age, disease, medication status.
Body composition (body weight, body water content, muscle mass, body fat content, body fat percentage, basal metabolic rate, visceral fat level, BMI)
Vascular index: ABI, PWV
Muscle output: knee extensor strength, ankle plantar flexor strength
Blood test data: HbA1C
From the above, DM-related items are defined as HbA1c, DM duration, PWV, and ABI. The methods of measurement are described in the following sections.
Observational
20 | years-old | <= |
Not applicable |
Male and Female
Eligible patients are outpatients undergoing treatment for type II DM.
Patients with musculoskeletal disorders of the lower extremities (not excluded if there is no swelling in the lower extremities), amputees, patients with obvious paralysis due to central nervous system disorders, patients with arteriosclerosis obliterans, patients with malignant neoplasms, pregnant women or women suspected of pregnancy, and patients with intracorporeal devices such as cardiac pacemakers.
150
1st name | TOMOKI |
Middle name | |
Last name | furuya |
Dokkyo Medical University Nikko Medical Center,
Department of Cardiovascular Medicine and Nephrology,
321-2593
632 Takatoku, Nikko-city, Tochigi, Japan
0288-76-1515
furuya19870818@gmail.com
1st name | TOMOKI |
Middle name | |
Last name | furuya |
Dokkyo Medical University Nikko Medical Center,
Department of Cardiovascular Medicine and Nephrology,
321-2593
632 Takatoku, Nikko-city, Tochigi, Japan
0288-76-1515
furuya19870818@gmail.com
Dokkyo Medical University Nikko Medical Center,
Japan Science and Technology Agency (JST)
Japanese Governmental office
Dokkyo Medical University Nikko Medical Center,
632 Takatoku, Nikko-city, Tochigi, Japan
0288-76-1515
furuya19870818@gmail.com
NO
2021 | Year | 09 | Month | 10 | Day |
Unpublished
128
No longer recruiting
2021 | Year | 09 | Month | 10 | Day |
2020 | Year | 07 | Month | 27 | Day |
2021 | Year | 09 | Month | 10 | Day |
2021 | Year | 09 | Month | 10 | Day |
unspecified
2021 | Year | 09 | Month | 10 | Day |
2021 | Year | 09 | Month | 10 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000051881